Tags

Type your tag names separated by a space and hit enter

Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer.
Ann Thorac Surg. 2006 Jul; 82(1):214-8; discussion 219.AT

Abstract

BACKGROUND

Thoracoscopic lobectomy is an accepted oncologic approach for early stage non-small cell lung cancer (NSCLC). We conducted a retrospective study of patients who underwent lobectomy after induction therapy to determine the feasibility of thoracoscopic lobectomy compared with conventional thoracotomy lobectomy.

METHODS

The outcomes of 97 consecutive patients with NSCLC who received induction therapy followed by lobectomy from 1996 to 2005 were reviewed. Outcome variables analyzed included complete resection, chest tube duration, length of hospitalization, 30-day mortality, hemorrhage, pneumonia, respiratory failure, and other major complications. The Student t test and chi2 or RxC contingency tables were used to compare continuous and categoric variables, respectively.

RESULTS

Lobectomy was performed by thoracotomy in 85 patients and thoracoscopically in 12 patients (1 conversion), with complete resection in all patients. All patients received induction chemotherapy, and 74 (76%) received induction radiotherapy as well: 66 of 85 (78%) in the thoracotomy group and 8 of 12 (67%) in the thoracoscopy group. The overall median survival was 2.3 years, with no difference between the groups. Patients undergoing a thoracoscopic lobectomy had a shorter median hospital stay (3.5 vs 5 days, p = 0.0024) and chest tube duration (2 vs 4 days, p < 0.001). There were no significant differences in 30-day mortality, hemorrhage, pneumonia, or respiratory failure.

CONCLUSIONS

Thoracoscopic lobectomy is a feasible approach for selected patients undergoing resection after induction therapy, and is associated with shorter hospital stay and chest tube duration. Long-term follow-up of survival will determine the role of thoracoscopic lobectomy in the management of patients after induction therapy.

Authors+Show Affiliations

Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article

Language

eng

PubMed ID

16798217

Citation

Petersen, Rebecca P., et al. "Thoracoscopic Lobectomy: a Safe and Effective Strategy for Patients Receiving Induction Therapy for Non-small Cell Lung Cancer." The Annals of Thoracic Surgery, vol. 82, no. 1, 2006, pp. 214-8; discussion 219.
Petersen RP, Pham D, Toloza EM, et al. Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer. Ann Thorac Surg. 2006;82(1):214-8; discussion 219.
Petersen, R. P., Pham, D., Toloza, E. M., Burfeind, W. R., Harpole, D. H., Hanish, S. I., & D'Amico, T. A. (2006). Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer. The Annals of Thoracic Surgery, 82(1), 214-8; discussion 219.
Petersen RP, et al. Thoracoscopic Lobectomy: a Safe and Effective Strategy for Patients Receiving Induction Therapy for Non-small Cell Lung Cancer. Ann Thorac Surg. 2006;82(1):214-8; discussion 219. PubMed PMID: 16798217.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer. AU - Petersen,Rebecca P, AU - Pham,Duykhanh, AU - Toloza,Eric M, AU - Burfeind,William R, AU - Harpole,David H,Jr AU - Hanish,Steven I, AU - D'Amico,Thomas A, PY - 2005/11/06/received PY - 2006/02/13/revised PY - 2006/02/22/accepted PY - 2006/6/27/pubmed PY - 2006/8/15/medline PY - 2006/6/27/entrez SP - 214-8; discussion 219 JF - The Annals of thoracic surgery JO - Ann Thorac Surg VL - 82 IS - 1 N2 - BACKGROUND: Thoracoscopic lobectomy is an accepted oncologic approach for early stage non-small cell lung cancer (NSCLC). We conducted a retrospective study of patients who underwent lobectomy after induction therapy to determine the feasibility of thoracoscopic lobectomy compared with conventional thoracotomy lobectomy. METHODS: The outcomes of 97 consecutive patients with NSCLC who received induction therapy followed by lobectomy from 1996 to 2005 were reviewed. Outcome variables analyzed included complete resection, chest tube duration, length of hospitalization, 30-day mortality, hemorrhage, pneumonia, respiratory failure, and other major complications. The Student t test and chi2 or RxC contingency tables were used to compare continuous and categoric variables, respectively. RESULTS: Lobectomy was performed by thoracotomy in 85 patients and thoracoscopically in 12 patients (1 conversion), with complete resection in all patients. All patients received induction chemotherapy, and 74 (76%) received induction radiotherapy as well: 66 of 85 (78%) in the thoracotomy group and 8 of 12 (67%) in the thoracoscopy group. The overall median survival was 2.3 years, with no difference between the groups. Patients undergoing a thoracoscopic lobectomy had a shorter median hospital stay (3.5 vs 5 days, p = 0.0024) and chest tube duration (2 vs 4 days, p < 0.001). There were no significant differences in 30-day mortality, hemorrhage, pneumonia, or respiratory failure. CONCLUSIONS: Thoracoscopic lobectomy is a feasible approach for selected patients undergoing resection after induction therapy, and is associated with shorter hospital stay and chest tube duration. Long-term follow-up of survival will determine the role of thoracoscopic lobectomy in the management of patients after induction therapy. SN - 1552-6259 UR - https://www.unboundmedicine.com/medline/citation/16798217/Thoracoscopic_lobectomy:_a_safe_and_effective_strategy_for_patients_receiving_induction_therapy_for_non_small_cell_lung_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0003-4975(06)00393-6 DB - PRIME DP - Unbound Medicine ER -